Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Urinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis

  • Martinez-Marzo, Eva
  • Peran, Maria
  • Lerma-Irureta, Juan
  • Medel-Martinez, Ana
  • Paules, Cristina
  • Oros, Daniel
  • Fabre, Marta
Introduction: Placental growth factor (PlGF) is a key biomarker for diagnosing and predicting preeclampsia (PE). While serum-based PlGF assays are well established, urine has emerged as a promising non-invasive alternative matrix. However, the absence of urinary PlGF stability data remains a major preanalytical limitation. This study aimed to assess urinary PlGF stability under common preanalytical conditions, including refrigerated storage and a double freeze-thaw cycle. Materials and methods: A prospective study was conducted using urine samples from ten pregnant women. Each sample was processed under standard laboratory conditions and aliquoted into five tubes. One aliquot was immediately frozen at - 80 °C (T0), three were stored at 2-8 °C for 48, 96, and 168 hours before freezing, and one underwent a double freeze-thaw cycle. Urinary PlGF concentrations were measured using the Elecsys PlGF immunoassay on Roche Cobas e801 analyzer. Percent degradation (PD%) was calculated relative to baseline. A linear regression model was applied to estimate the time to exceed a maximum permissible instability (MPI) of ± 10 %. Results: Urinary PlGF remained stable at 2-8 °C for up to 48 hours, with a mean PD% of - 6 % (95% confidence interval (CI): - 9.1 to - 2.8). The regression model (PD% = - 0.0834 x Time (h)) estimated the - 10 % threshold at approximately 120 hours. After a double freeze-thaw cycle, the mean PD% was - 1.5 % (95% CI: - 3.4 to 0.4%). Conclusions: Urinary PlGF shows acceptable stability for up to 48 hours under refrigeration and is stable over two freeze-thaw cycles. These findings provide essential preanalytical data supporting its potential use in clinical and research settings.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Towards an understanding of COVID-19-associated preeclampsia

  • Medel-Martinez, A.
  • Cebollada-Solanas, A.
  • Strunk, M.
  • Fabre, M.
  • Fernández-Soria, V. M.
  • Ramos-Ruiz, R.
  • Paules, C.
  • Oros, D.
  • Schoorlemmer, J.
Introduction SARS-CoV-2 infection during pregnancy has been associated with higher rates of preeclampsia (PE). While placental abnormalities resembling PE have been reported in COVID-19 pregnancies, the molecular mechanisms underlying the association remain unclear. Methods We conducted bulk RNA sequencing on placental tissues from four pregnancy groups: uneventful prepandemic (preCOVID-19), prepandemic PE (preCOVID-19 PE), COVID-19 without PE (COVID no PE), and COVID-19 complicated by PE or other hypertensive disorders (COVID PE). Differential expression was analyzed using Deseq2 likelihood ratio test (LRT), and gene set enrichment analysis identified dysregulated pathways. Results Clustering of LRT-significant differentially expressed genes (DEGs) identified a set of 16 genes (defined by the false discovery rate adjusted p-value < 0.05) across the four pregnancy groups, showing stepwise expression changes—lowest in preCOVID-19 uneventful, followed by those in COVID-19 without PE, then preCOVID-19 PE, and highest in COVID PE. This cluster included genes associated with placental dysfunction, such as LAMA5 and BTNL9. While morphogenesis-related pathways were enriched across all pathological groups, immune activation pathways were predominantly enriched in COVID PE, moderately in preCOVID-19 PE, and absent in COVID no PE. Discussion Our findings identify a COVID-19–associated placental signature that mirrors PE features and shows a progressive expression pattern defining a continuum of placental stress, with maternal SARS-CoV-2 infection potentially exacerbating underlying dysfunction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Alterations of placental HERV expression as a result of gestational COVID-19 disease

  • Medel-Martinez, Ana
  • Bugatti, Mattia
  • Polychronopoulou, Mariana
  • Strunk, Mark
  • Macías-Redondo, Sofía
  • Bazo, Andrea
  • Garrido-Pontnou, Marta
  • Kitsou, Konstantina
  • Fabre, Marta
  • Paules, Cristina
  • Oros, Daniel
  • Pierquin, Justine
  • Brunel, Joanna
  • Charvet, Benjamin
  • Perron, Hervé
  • Facchetti, Fabio
  • Magiorkinis, Gkikas
  • Schoorlemmer, Jon
Introduction: Activation of human endogenous retroviral elements (HERV) is a well-documented phenomenon in inflammatory pathologies including COVID-19, with HERVW ENV frequently mentioned as a toxic protein. Given that COVID-19 during pregnancy has been associated with placental damage and a higher risk of adverse pregnancy outcomes (APOs), we investigated whether gestational COVID-19 alters placental HERV expression, and if such alterations correlate with placental damage or dysfunction. Methodology and results: We quantitively analyzed mRNA expression of HERV in placental samples using qPCR assays rigorously tested for efficiency and specificity or transcriptomic analysis. Combined qPCR and transcriptomic analyses of placentas from maternal COVID-19 cases revealed an overall trend toward reduced expression of several HERV elements, including HERVW ENV-related transcripts, with a more pronounced downregulation in SARS-CoV-2-positive placentas. HERVW ENV protein was detected by immunofluorescence in the syncytiotrophoblast (STB), co-staining with HCGβ, using conditions minimizing cross-reactivity with ERVWE1. HERVW ENV protein levels were diminished in COVID-19 patients, especially in those cases in which SARS-CoV-2 was present in the placenta. Conclusions and discussion: While HERV expression is reportedly induced in blood lymphocytes and other tissues as a response to SARS-CoV-2 infection, we detect unaltered or lower RNA levels of selected retroviral elements in the placenta of COVID-19 patients. HERVW ENV protein was present in non-COVID-19 placenta, and downregulated by maternal COVID-19 disease. The absence of HERVW ENV protein induction was confirmed by the careful study of cases with placental SARS-CoV-2 infection, as HERVW ENV was mostly absent from these samples, probably as an indirect result of placental damage. We identified two independent triggers for the downregulation of both HERVW ENV RNA and protein in placenta: maternal COVID-19 and local effects of SARS-CoV-2. Therefore, this HERV downregulation may represent part of the molecular response to placental SARS-CoV-2 infection, contributing to placental dysfunction and APOs.